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Objectives We sought to create contemporary models for predicting mortality risk following percutaneous coronary
intervention (PCI).
Background There is a need to identify PCI risk factors and accurately quantify procedural risks to facilitate comparative ef-
fectiveness research, provider comparisons, and informed patient decision making.
Methods Data from 181,775 procedures performed from January 2004 to March 2006 were used to develop risk models
based on pre-procedural and/or angiographic factors using logistic regression. These models were independently
evaluated in 2 validation cohorts: contemporary (n  121,183, January 2004 to March 2006) and prospective
(n  285,440, March 2006 to March 2007).
Results Overall, PCI in-hospital mortality was 1.27%, ranging from 0.65% in elective PCI to 4.81% in ST-segment eleva-
tion myocardial infarction patients. Multiple pre-procedural clinical factors were significantly associated with in-
hospital mortality. Angiographic variables provided only modest incremental information to pre-procedural risk
assessments. The overall National Cardiovascular Data Registry (NCDR) model, as well as a simplified NCDR risk
score (based on 8 key pre-procedure factors), had excellent discrimination (c-index: 0.93 and 0.91, respectively).
Discrimination and calibration of both risk tools were retained among specific patient subgroups, in the valida-
tion samples, and when used to estimate 30-day mortality rates among Medicare patients.
Conclusions Risks for early mortality following PCI can be accurately predicted in contemporary practice. Incorporation of
such risk tools should facilitate research, clinical decisions, and policy applications. (J Am Coll Cardiol 2010;
55:1923–32) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.005P
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010, accepted February 9, 2010.ercutaneous coronary intervention (PCI) has become one
f the most widely applied treatments in current-day car-
iology, facilitating the relief of angina and (in the setting
f acute ST-segment elevation myocardial infarction
STEMI]), saving lives (1). Although the periprocedural
omplications of PCI have declined over time, tangible risks
emain. Estimating patients’ PCI mortality risk is important
or several reasons. At the individual-patient level, knowing
ne’s procedural risk can help physicians and patients make
nformed clinical decisions (2). Identification and quantifi-
ation of clinical factors associated with procedural risk can
lso facilitate observational comparative effectiveness re-
earch (3). Finally, at a policy level, predicted risk estimates
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Mortality Prediction in PCI May 4, 2010:1923–32can help “level the playing field”
of provider outcome metrics,
helping to adjust for potential
differences in cases treated (4).
To date, several PCI mortality
risk models have been published.
Yet many have become outdated
and do not reflect contemporary
care or outcomes (5–13). Other
risk models were developed on
select populations and may not
be generalizable (7–9,11,14–19).
Additionally, many models failed
to consider angiographic features
that are associated with proce-
dural risk (9,20,21). The Na-
tional Cardiovascular Data Reg-
istry (NCDR) for catheterization
percutaneous coronary interven-
tion (CathPCI) provides the
ideal infrastructure to derive pro-
cedure risk models in a national
representative contemporary U.S.
sample. This database has a very
large patient population, con-
ains rich and complete clinical information, and is reflective
f contemporary practice.
See page 1933
Using the NCDR CathPCI database, our goals were to:
) develop PCI risk tools for estimating mortality risks for
oth elective and primary PCI; 2) determine the incremen-
al prognostic value of angiographic details beyond pre-
rocedural risk factors; 3) develop a simplified, user-
riendly, PCI risk score; 4) internally validate the PCI risk
odel and risk score in important subpopulations; and
) assess the models’ ability to estimate 30-day PCI mor-
ality risk among Medicare patients whose status is defined
ia claims data.
ethods
he NCDR CathPCI Registry database. The NCDR
athPCI Registry is cosponsored by the American College
f Cardiology and the Society for Cardiovascular Angiog-
aphy and Interventions (22,23). The registry catalogs
ata on patient characteristics, clinical features, angio-
raphic and procedural details, and in-hospital outcomes.
articipating centers agree to submit complete information
nd outcomes from consecutive interventional cases per-
ormed at their institutions. The NCDR also has a com-
rehensive data quality program, including data abstraction
raining, data quality thresholds for inclusion, site data
uality feedback reports, independent auditing, and data
Abbreviations
and Acronyms
BMI  body mass index
CathPCI  catheterization
percutaneous coronary
intervention
CHF  congestive heart
failure
CMS  Centers for
Medicare and Medicaid
Services
EF  ejection fraction
GFR  glomerular filtration
rate
NCDR  National
Cardiovascular Data
Registry
NYHA  New York Heart
Association
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionalidation (22). Data elements and definitions are available at: mttp://www.ncdr.com/WebNCDR/ELEMENTS.ASPX#1.
he Duke Clinical Research Institute (DCRI) serves as the
rimary analytic center for the CathPCI Registry, and per-
ormed the analyses for this report.
ariable selection. The NCDR established a risk adjust-
ent model committee of American College of Cardiology
olunteers to provide oversight for model development,
ncluding input on candidate variable selection and review of
he model results. This group strictly adhered to current
tandards of model creation (24). The outcome of interest
or these models was all-cause in-hospital mortality. Can-
idate variables were selected based on their relevance, as
dentified in prior research, or as identified in the commit-
ee’s clinical experience.
issing data. The rates of overall missing data in the
CDR CathPCI database are very low. Of the final model
ariables, only ejection fraction (EF) percentage had more
han a 5% rate of missing data. For those few cases that
ontained missing information, the following imputation
ules were used: 1) for elements dealing with a patient’s past
edical history, use of a pre-procedural intra-aortic balloon
ump, presence of subacute thrombosis, and coronary lesion
ith highest risk lesion, missing data were imputed to “no”;
) for body mass index (BMI), missing values were imputed
o the gender-specific median; 3) for glomerular filtration
ate (GFR), missing values were imputed to the gender-,
rior renal failure-, and STEMI-specific median; and 4) for
F, missing data were imputed by stratifying the population
ased on a history of congestive heart failure (CHF), prior
yocardial infarction, pre-procedural cardiogenic shock,
nd the presence of STEMI. Neither age nor the Society for
ardiovascular and Angiography and Interventions Lesion
lass were imputed. We also performed a sensitivity anal-
sis using multiple imputation methods. However, these
esults were nearly identical to the overall findings and are,
herefore, not presented.
opulation definition. Two separate patient populations
ere identified: one for model development and one for
rospective validation. For the model development phase,
atients were included if they received their first PCI
rocedure at any of the 470 hospitals submitting PCI
ecords between January 1, 2004, and March 30, 2006.
atients were excluded if they transferred out or were
issing more than 2 candidate variables (Fig. 1). The
odel development population was further randomly
llocated to an initial model development dataset (60% of
otal), and a second group (40% of total) was used for an
nitial validation sample. A second prospective validation
ample was identified from cases performed at the 608 NCDR
ospitals submitting PCI cases between March 31, 2006, and
arch 30, 2007, using the same inclusion and exclusion
riteria as noted in the previous text (Fig. 1).
Additionally, we examined the robustness of our models
o predict 30-day mortality, as opposed to in-hospital
ortality, in a Medicare-eligible population (25). Since
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May 4, 2010:1923–32 Mortality Prediction in PCIutcomes beyond the initial hospital stay are not routinely
ollected in the NCDR, we linked NCDR records for those
ge 65 years or older to the national Centers for Medicare
nd Medicaid Services (CMS) inpatient claims data. The
rocess used to do this has been previously described (26).
or this specific linkage to occur, we began with Medicare-
ligible NCDR CathPCI patients undergoing a PCI pro-
edure between January 2005 and December 2006 (the last
vailable data from CMS). Of the possible 348,370 records,
Figure 1 Population Flow Diagram
Between January 2004 and March 2007, 600,533 PCI admissions were recorded
Coronary Intervention (CathPCI) Registry. Following exclusions, 588,398 total patie
STEMI  ST-segment elevation myocardial infarction.e linked 253,081 records (72.7%), representing 204,111 pnique patients. Baseline characteristics of the linked pop-
lation and unlinked records were similar.
tatistical methods. An initial candidate variable list was
enerated using clinical judgment and prior known PCI risk
actors. Univariate analysis was then used to identify which
f the potential candidate variables had a statistical associ-
tion with in-hospital mortality (e.g., p  0.05). Based on
his univariate analysis, the risk adjustment model commit-
ee selected the most clinically meaningful variables as
National Cardiovascular Data Registry (NCDR) Catheterization Percutaneous
re included in the overall model development and validation cohort.in the
nts weotential candidates for inclusion in the multivariable
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Mortality Prediction in PCI May 4, 2010:1923–32odel. Multivariate logistic regression with a backward
election method (p  0.05 to remain in the model) was
hen performed to identify independent predictors of
utcomes.
Three separate models were developed. First, a “full”
odel was created, which included all candidate variables
e.g., demographic, pre-catheterization clinical variables,
nd angiographic variables). Second, we contrasted this full
odel with a second “pre-cath” model, excluding detailed
CDR angiographic data. This second model assessed the
Patient Clinical CharacteristicsTable 1 Patient Clinical Characteristics
Developme
(n  181,7
Patient characteristics
Age 63.9 12
Female 33.4%
Caucasian 87.2%
BMI (kg/m2) 29.6 6
Prior MI (7 days) 29.1%
Prior CHF 10.1%
Diabetes
Noninsulin 21.5%
Insulin 10.0%
Mean GFR (MDRD) 73.6 30
Dialysis 1.6%
Cerebral vascular disease 10.9%
Peripheral vascular disease 11.7%
CLD 16.0%
Prior PCI 35.1%
NYHA functional class IV 18.3%
Cardiogenic shock 1.9%
Hospital characteristics
Number of beds 463 22
Location
Rural 12.6%
Urban 61.0%
Teaching 60.1%
Region
West 14.1%
Northeast 9.0%
Midwest 36.9%
South 36.5%
Mean annual PCI volume 666 55
Procedural characteristics
LVEF 52.7 12
PCI status
Elective 49.3%
Urgent 36.1%
Emergency 14.4%
Salvage 0.2%
Highest risk coronary segment
pLAD 18.2%
Left main 1.7%
TIMI flow grade 0 11.0%
Multivessel PCI 14.0%
BMI  body mass index; CHF  congestive heart failure; CLD  chronic
fraction; MDRDModification of Diet in Renal Disease; MImyocardial infarct
intervention; pLAD  proximal left anterior descending artery; TIMI Thrombolyncremental value of angiographic information for mortality
rediction. Finally, we developed a “limited” pre-cath risk
rediction model, which included only those variables with
he strongest explanatory power based on their Wald
hi-square value. The regression coefficients from the sim-
lified pre-cath model were then converted into whole
ntegers to create an NCDR CathPCI Risk Prediction score
27).
odel performance characteristics. After development,
e applied these 3 models to the prospective validation
1st Validation
(n  121,183)
2nd Validation
(n  285,440)
63.9 12.1 64.1 12.1
33.3% 33.3%
87.1% 85.6%
29.7 6.3 29.8 6.3
29.1% 27.3%
10.0% 9.9%
21.7% 22.3%
10.0% 10.3%
73.5 29.0 73.2 28.1
1.5% 1.5%
11.1% 11.1%
11.7% 11.9%
16.0% 15.8%
35.4% 36.6%
18.3% 18.8%
1.8% 1.7%
463 220 454 225
12.6% 12.1%
61.3% 61.2%
60.0% 54.6%
14.3% 16.2%
9.9% 10.4%
36.7% 35.8%
36.8% 37.6%
668 550 679 573
52.7 12.7 52.7 12.7
49.3% 50.2%
35.6% 34.7%
14.5% 15.0%
0.2% 0.2%
18.2% 18.2%
1.8% 1.8%
10.7% 14.9%
13.9% 14.1%
sease; GFR  glomerular filtration rate; LVEF  left ventricular ejectionnt
75)
.1
.3
.5
1
0
.7
lung di
ion; NYHA New York Heart Association; PCI percutaneous coronary
sis In Myocardial Infarction.
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May 4, 2010:1923–32 Mortality Prediction in PCIample sets. Model discrimination was assessed using the
-index. A model c-index can range from 0.50 (no predictive
alue) to 1.0 (perfect prediction). To assess model calibra-
ion, patients were rank-ordered from lowest- to highest-
redicted risk. Comparison was then made of predicted
ersus observed event rates within risk strata. Model dis-
rimination and calibration were assessed in the overall
opulation, within the 2 validation samples, and among
elect subpopulations of both of these groups. Finally, we
ssessed the models’ discrimination among patients age 65
ears who had been linked to CMS data to assess both
n-hospital and 30-day mortality.
esults
etween January 2004 and March 2007, 600,533 consecu-
ive PCI admissions were recorded in the NCDR CathPCI
egistry. Following exclusions, 588,398 total patients were
ncluded in our overall model development and validation
ohort. From this population, a model development sample
n  181,775) was created from a random sample com-
rised of two-thirds the cases performed between January
004 and March 2006. The final one-third of these cases
as used to create a contemporary model validation sample
n  121,183). Cases performed between March 2006 and
arch 2007 were used as a prospective validation sample
n  285,440) (Fig. 1).
Table 1 provides demographic, clinical, and angiographic
eatures of those patients in the development set, as well as
n the 2 validation sets. The mean patient age was 64 years,
3% were female, 32% had diabetes mellitus, and 10% had
prior history of CHF. Overall, 51% of the patients
nderwent nonelective procedures, and 14% underwent
ultivessel PCI. The results were similar across the 3
amples, except that in-hospital mortality was slightly lower
n the second prospective validation sample (1.17%), relative
o the other 2 samples (1.24% and 1.27%).
isk factors for in-hospital mortality. Table 2 provides
nadjusted In-Hospital Mortality (%)Table 2 Unadjusted In-Hospital Mortality (%)
Development
(n  181,775)
1st Validation
(n  121,183)
2nd Validation
(n  285,440)
Overall population 1.24 1.27 1.17
MI status
STEMI 4.81 4.79 4.69
No STEMI 0.65 0.69 0.60
Gender
Men 1.04 1.07 1.00
Women 1.63 1.67 1.50
Age group
Age 70 yrs 2.25 2.32 2.02
Age  70 yrs 0.76 0.77 0.76
Diabetes status
Diabetes 1.44 1.50 1.30
No diabetes 1.15 1.16 1.11
I  myocardial infarction; STEMI  ST-segment elevation myocardial infarction.bserved in-hospital mortality rates for various patient aubgroups. These mortality rates ranged from 0.65% in the
on-primary PCI population to 4.81% in the STEMI
opulation (Table 2). Older patients, women, and diabetic
atients experienced higher unadjusted in-hospital mortality
ates than younger patients, men, and non-diabetic patients
2.25% vs. 0.76%, 1.63% vs. 1.04%, and 1.44% vs. 1.15%,
espectively).
Table 3 provides the final full model, which includes 21
eparate clinical variables, as well as interaction terms for
TEMI/shock, BMI, GFR, dialysis, New York Heart
ssociation (NYHA) functional class, highest-risk lesion
egment category, and PCI status. When model chi-square
alue was used as the metric, cardiogenic shock was the
ost predictive of in-hospital mortality, followed by renal
unction (estimated glomerular filtration rate [eGFR]) and
ge. In contrast, angiographic predictors were generally less
rognostic. The angiographic feature most highly associated
ith in-hospital mortality was lesion location (e.g., left main
esions and proximal left anterior descending lesions).
CDR PCI bedside risk prediction score. Predictors
ontaining the strongest association with mortality are
escribed in Table 3. These risk factors were then converted
o an integer score (based on their relative magnitude of
ssociation with mortality), to create the NCDR CathPCI
isk Prediction Score (Table 4). Using this scoring system,
he risk of in-hospital mortality can be estimated by sum-
ating point scores between 0 and 100.
odel performance. The full NCDR CathPCI Mortality
isk Prediction model in the contemporary and prospective
alidation cohorts performed exceptionally well, with a
-index of 0.925 and 0.924, respectively. Additionally, the
ull model performed well in each of the 8 predefined
atient subgroups, with c-indices ranging from 0.892 to
.930 (Table 5). Of note, the exclusion of angiographic
etails and EF from the full model resulted in only a slight
ecrement in the overall model accuracy. Similarly, there
as limited loss in model discrimination when the model
as transformed into the final, simplified NCDR CathPCI
isk Score, with c-indices of 0.901 and 0.905, respectively,
n the validation samples. This simplified score also had
ood operating characteristics in all predefined patient
ubgroups.
Model calibration plots are shown in Figures 2 and 3.
otably, the majority of patients had a relatively low
ortality risk (92.6% of patients had a predicted mortality
isk between 0% and 2.5%). However, there was high
oncordance between model predicted risk and that which
as actually observed. The simplified NCDR CathPCI
isk Score was also well calibrated in both low- and
oderate-risk populations, with only a slight underestima-
ion of predicted risk in high-risk patients (Fig. 3).
Finally, we examined the full and simplified models’
bility to estimate 30-day mortality among patients age 65
ears or older who had been linked to CMS data. Among
04,111 Medicare patients, 4,068 (1.99%) died in-hospital
nd 6,011 (2.94%) died within 30 days of the procedure.
F*
A
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Mortality Prediction in PCI May 4, 2010:1923–32ull and Pre-Cath Simplified Risk ModelsTable 3 Full and Pre-Cath Simplified Risk Models
Label
Full Model Pre-Cath Model
Odds Ratio
95% Confidence
Interval Chi-Square Odds Ratio
95% Confidence
Interval Chi-Square
Intercept 171.14 708.97
STEMI patients 1.77 44.55
Cardiogenic shock at admission 8.35 7.40–9.44 1,168.28 12.19 10.86–13.68 1,804.73
PCI status
For STEMI
Urgent 1.09 0.64–1.83 0.09 1.25 0.75–2.07 0.71
Emergency 2.07 1.30–3.31 9.24 2.65 1.68–4.18 17.58
Salvage 14.55 8.39–25.21 91.08 21.45 12.57–36.61 126.36
For no STEMI
Urgent 2.01 1.70–2.39 63.91 2.49 2.11–2.95 114.46
Emergency 7.29 5.91–8.99 343.95 11.79 9.69–14.34 606.91
Salvage 82.54 45.83–148.63 216.24 146.55 82.60–260.04 290.59
Age*
For age 70 yrs 1.71 1.57–1.88 125.80 1.76 1.60–1.91 150.93
For age 70 yrs 1.55 1.44–1.69 115.33 1.52 1.40–1.64 107.92
GFR*
For STEMI 0.77 0.74–0.80 181.90 0.77 0.75–0.78 377.55
For no STEMI 0.82 0.78–0.85 100.96
NYHA functional class IV
For no STEMI 1.74 1.50–2.02 52.82 1.61 1.46–1.79 81.71
For STEMI 1.21 1.05–1.39 6.74
Chronic lung disease 1.48 1.31–1.66 43.04 1.52 1.36–1.71 52.87
Peripheral vascular disease 1.53 1.35–1.74 42.39 1.67 1.48–1.89 67.78
Previous history of CHF 1.29 1.13–1.47 13.85 1.75 1.54–1.98 77.25
Ejection fraction percentage* 0.73 0.70–0.76 234.09
Highest risk lesion: SCAI lesion class
IV vs. I 2.05 1.70–2.47 57.40
II or III vs. I 1.47 1.29–1.67 33.84
Diabetes/control
Insulin diabetes vs. no diabetes 1.78 1.53–2.07 56.24
Noninsulin diabetes vs. no diabetes 1.11 0.98–1.25 2.47
Highest risk lesion: segment category
For STEMI
Left main 5.54 3.43–8.93 49.26
pLAD 1.52 1.26–1.83 19.00
pRCA/mLAD/pCIRC 1.34 1.13–1.59 11.18
Previous PCI 0.69 0.61–0.78 36.59
BMI, kg/m2†
For no STEMI 0.76 0.69–0.83 33.91
For STEMI 0.93 0.85–1.03 1.97
Pre-op IABP 3.14 2.12–4.65 32.64
For no STEMI
pLAD 1.65 1.38–1.98 29.257
Left main 2.33 1.71–3.17 28.586
pRCA/mLAD/pCIRC 1.26 1.07–1.48 7.721
Subacute thrombosis? Yes vs. no 1.96 1.41–2.72 16.21
Cerebrovascular disease 1.26 1.11–1.44 12.02
Previous vascular disease 1.58 1.10–2.26 6.02
Highest risk pre-procedure 1.19 1.02–1.38 4.84
TIMI flow  0 vs. other
Per 10-U increase; †per 5-U increase.
IABP  intra-aortic balloon pump; mLAD  mid left anterior descending artery; pRCA  proximal right coronary artery; pCIRC  proximal left circumflex artery; SCAI  Society for Cardiovascular
ngiography and Interventions; STEMI  ST-segment elevation myocardial infarction; other abbreviations as in Table 1.
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May 4, 2010:1923–32 Mortality Prediction in PCI-indices for the full model in this population were: c 
.90 for in-hospital and c  0.86 for 30-day mortality,
espectively. C-indices for the Simplified Risk Score in this
opulation were: c  0.89 for in-hospital and c  0.83 for
0-day mortality, respectively.
iscussion
espite tremendous advances in PCI over the past decade,
arly periprocedural mortality remains a concern. Using data
rom the NDCR, we identified demographics, clinical
actors, and angiographic features associated with PCI
n-hospital mortality. These were summarized into a full
NCDR CathPCI Risk Score SystemTable 4 NCDR CathPCI Risk Score System
Variable Scoring Respons
Age 60 60,70
0 4
Cardiogenic shock No Yes
0 25
Prior CHF No Yes
0 5
Peripheral vascular disease No Yes
0 5
Chronic lung disease No Yes
0 4
GFR 30 30–60
18 10
NYHA functional class IV No Yes
0 4
PCI status (STEMI) Elective Urgent
12 15
PCI status (no STEMI) Elective Urgent
0 8
CathPCI  Catheterization Percutaneous Coronary Intervention; NCDR
and 3.
C-Indices for NCDR ModelsTable 5 C-Indices for NCDR Models
Sample, n (Pre-C
Development 181,775
1st validation 121,183
2nd validation 285,440
Subgroups (in 2nd validation)
STEMI 39,889
No STEMI 245,551
Women 95,106
Men 190,334
Age 70 yrs 92,381
Age 70 yrs 193,059
Diabetes 92,974
No diabetes 192,466Cath  catheterization; NCDR  National Cardiovascular Data Registry; STEMisk model (with both pre-procedure and angiographic
eatures) and a simplified 8-item NCDR CathPCI Risk
core, to support both robust hospital outcome comparisons
nd patient-level pre-procedural risk estimation, respec-
ively. Both the full and simplified models retain their
redictive accuracy in important patient subsets, in separate
nternal validation samples, and when estimating 30-day
ortality in Medicare patients.
Several risk-adjustment models have been previously devel-
ped for the prediction of mortality following PCI. However,
any of these were developed using data that predates the
eneralized use of stents and/or contemporary adjuvant anti-
hrombotic therapy (5–13). Other models have been developed
egories Total Points
Risk of In-Patient
Mortality
80 80 0 0.0%
14 5 0.1%
10 0.1%
15 0.2%
20 0.3%
25 0.6%
30 1.1%
35 2.0%
40 3.6%
45 6.3%
90 90 50 10.9%
0 55 18.3%
60 29.0%
65 42.7%
gent Salvage 70 57.6%
38 75 71.2%
gent Salvage 80 81.0%
42 85 89.2%
90 93.8%
95 96.5%
100 98.0%
onal Cardiovascular Data Registry; other abbreviations as in Tables 1
Model
Cath Factors)
Pre-Cath
Model Only
NCDR Simplified
Risk Score
.926 0.911 0.911
.925 0.905 0.901
.924 0.910 0.905
.902 0.890 0.884
.892 0.896 0.862
.911 0.897 0.893
.930 0.916 0.911
.901 0.886 0.88
.927 0.911 0.906
.924 0.910 0.903
.923 0.910 0.906e Cat
70,
8
60–
6
Emer
20
Emer
20Full
ath 
0
0
0
0
0
0
0
0
0
0
0I  ST-segment elevation myocardial infarction.
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Mortality Prediction in PCI May 4, 2010:1923–32rom select referral centers or regional populations and may not
e as generalizable across the nation (7–9,11,14–19). Still,
ther models were developed using databases that in-
luded only elderly patients, or used administrative data
hich lacked the clinical details necessary to capture the
mportant clinical and angiographic risks factors associ-
ted with periprocedural mortality (9,20,21).
The models derived in this study expand on these prior
odels. First, the comprehensive and complete nature of
he NCDR’s clinical data allows for a more complete
ssessment of multiple risk predictors. For example, female
ex has long been a feature predictive in many prior studies,
et this feature is no longer significantly associated with
ortality after adjusting for multiple potential confounders
e.g., BMI, eGFR, and so on) and in the contemporary
opulations (28,29). Additionally, we have demonstrated
hat the inclusion of angiographic details (as they are
efined in the NCDR CathPCI Registry) to a pre-cath risk
rediction model, add marginal overall improvements in our
bility to predict in-hospital mortality. Rather, in-hospital
ortality was driven primarily by pre-existing patient co-
orbidities and markers of clinical instability. This finding
s consistent with the work of others (16) and has important
Figure 2 Calibration for the Full Model
Among Patients in the Validation Sample
Demonstrates observed versus predicted mortality estimates (and the 95%
confidence interval) for 10 equally sized risk groups of ST-segment elevation
myocardial infarction (A) and non–ST-segment elevation myocardial infarction
(B) patients, based on the full risk prediction model evaluated in the second
validation sample.linical implications in that it allows patients and physicianso obtain a reasonable estimate of procedural risk, prior to
ngiography.
In the aggregate population, angiographic risk factors
dded modest value, whereas in individual cases, their
mpact was more substantial. For example, the mean pre-
icted PCI risk for patients with left main stenosis was 4.5%
ersus 2.4%, depending on whether or not the prediction
ncluded the angiographic left main risk feature. Other risk
cores (such as the SYNTAX score), which arguably focus
ore heavily on collecting exhaustive angiographic data,
ave found some additional benefit from these angiographic
ariables (30).
We also found that patients presenting for PCI in the
etting of STEMI, faced substantially higher procedural
isk. However, the scope and relative impact of risk factors
eeded to predict risk in acute versus elective cases, were
uite similar. Based on this observation, we were able to
evelop a unified model of risk estimation for all PCI cases,
s opposed to separate STEMI and elective models. This
nified model (e.g., the simplified NCDR PCI Mortality
isk Score) accurately predicts mortality in both acute and
lective cases.
tility of risk models. The NCDR CathPCI risk predic-
ion tools developed and validated in this analysis cover the
road spectrum of anticipated model uses and address the
eeds of researchers, administrators, physicians, and pa-
ients. The full NCDR model provides a comprehensive
ool to: 1) permit the most accurate adjustment of both
re-procedural and angiographic features for research
rojects; and 2) “level the playing field” for provider-level
ortality results comparisons. Yet the full model is complex,
Figure 3 Calibration of NCDR Bedside
Risk Score in Validation Sample
Based on their predicted risk, patients are grouped into 8 risk groups, using
the full risk prediction model, and then plotted again the observed mortality
rates for these in the second validation sample. NCDR  National Cardiovas-
cular Data Registry; PCI  percutaneous coronary intervention.
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May 4, 2010:1923–32 Mortality Prediction in PCInclusive of multiple data elements, spline-transformed
ontinuous variables, and interaction terms—thus, the
odel is not practical to estimate patients’ individual risk
ithout computer assistance. Therefore, we also created the
CDR CathPCI Risk Score, whose simplified 8-item
dditive risk score can be used for bedside risk estimation.
tudy limitations. Participation in the NCDR CathPCI
enters is voluntarily and slightly under-represents smaller
linical practices. That said, the NCDR CathPCI Registry
emains the largest, most generalizable U.S. data source.
n-patient mortality, rather than 30-day mortality, has limita-
ions as an end point (31). However, at the provider level,
n-hospital and 30-day mortality results are highly correlated.
dditionally, the only source of complete 30-day outcomes
s Medicare data, which do not capture outcomes in those
65 years of age. When our models were applied to predict
0-day mortality in the Medicare population, they retained
ood discrimination (c  0.86).
uture directions. As the practice of medicine continues
o evolve, so will the use of risk prediction models. Clini-
ally, computer-generated risk scores are being used to aid
n the personalization of the procedural consent process (2).
lthough mortality is clearly an important outcome, mod-
ling other modifiable outcomes, such as myocardial infarc-
ion, renal failure, bleeding complications, restenosis, stent
hrombosis, and angina relief, could further advance the
nstitute of Medicine’s goals for evidence-based, patient-
entered, medical care (2,32). As advanced procedural
upport devices (e.g., hemodynamic support devices) con-
inue to develop, risk prediction tools can be utilized to
ore clearly define the patient populations in which they
ill be maximally effective. From an administrative stand-
oint, the importance of these tools for provider-based
isk-adjusted outcomes comparisons will continue to in-
rease, as public reporting and pay-for-performance initia-
ives continue to grow in popularity. Finally, from a research
erspective, these risk tools will be used to mitigate treat-
ent selection bias when conducting comparative effective-
ess analyses in observational data.
onclusions
sing data from the NCDR CathPCI Registry, we have
eveloped and validated contemporary models for assessing
eriprocedural PCI mortality risk. Each of these has excellent
redictive accuracy throughout the full spectrum of patient
isk, and important patient subgroups. We anticipate that these
odels will have multiple applications (including bedside risk
stimation using the simplified risk score, comparison of
ospital performance, and risk adjustment).
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